Menu ×


Aplastic Anemia Treatment Market Segmentation by Treatment Type (Stem Cell Therapy, Blood Transfusion, Drug Therapy, and Others); by Disease Type (Acquired Aplastic Anemia and Inherited Aplastic Anemia); by Route of Administration (Intravenous, and Oral); and by End-User (Hospitals, Specialty Clinics, Research Institutes, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Aplastic Anemia Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • February, 2021: Sandoz announced the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio to production of antimicrobial drugs.

  •  September, 2020: Mylan and Pfizer received approval from European Commission for consolidation of Mylan and Upjohn for distribution in Europe.

Global Aplastic Anemia Treatment Market Highlights over 2022 – 2030

The global aplastic anemia treatment market is estimated to grow at a CAGR of ~5% over the forecast period, i.e., 2022 – 2030. Aplastic anemia is a rare genetic condition in which your body stops producing enough new blood cells. The growth of the market can be attributed to the increasing prevalence of aplastic anemia is estimated to boost the market growth. According to the National Organization for Rare Disorders (NORD), in the United States approximately 500-1,000 new cases of aplastic anemia are diagnosed each year, 4-6 cases in a million in Asia, and 2-3 cases in a million in Europe. Aplastic anemia is a type of aplasia, which is why, there is no cure available for this disease. Absence of aplasia treatment is estimated to boost the market growth. Moreover, the growing medical R&D activities aiming to develop treatment drugs for rare diseases, along with the growing investment in the field of research, are projected to boost the market growth. According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018.

Aplastic Anemia Treatment Market

The market is divided by disease type into acquired aplastic anemia and inherited aplastic anemia, out of which, the inherited aplastic anemia segment is anticipated to hold the notable share in the global aplastic anemia treatment market over the forecast period on account of high prevalence of this disorder amongst infants. Acquired aplastic anemia is more common in adults, while inherited aplastic anemia is prevalent in children.

On the basis of treatment type, the market is segmented into stem cell therapy, blood transfusion, drug therapy, and others, out of which, the stem cell therapy segment is projected to gain the highest revenue share during the forecast period. The growth of the segment can be attributed to the high success rate of stem cell therapy, in which, bone marrow is transfused to treat the lack of new blood cells. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Aplastic Anemia Treatment Market Regional Synopsis

On the basis of geographical analysis, the global aplastic anemia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of improving healthcare facilities, and economic development in countries, including, China, India, Japan, and others. 

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on the account of high cases of aplastic anemia in the region, growing healthcare expenditure, and increasing investment in medical research activities. According to the data by the World Bank, North America spent 2.734% of its GDP for R&D activities in 2018.

Aplastic AnemiaTreatment Market Share

The global aplastic anemia treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global aplastic anemia treatment market includes the following segments:

By Treatment Type

  • Stem Cell Therapy
  • Blood Transfusion
  • Drug Therapy
  • Others

By Disease Type

  • Acquired Aplastic Anemia
  • Inherited Aplastic Anemia

By Route of Administration

  • Oral
  • Intravenous

By End-User

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Others

Growth Drivers

  • Rising Prevalence of Aplastic Anemia
  • Increasing Investment in R&D Activities


  • Absence of Researchers and Scientists in Middle- and Low-Income Countries
  • High Cost of Treatment Options for Aplastic Anemia

Top Featured Companies Dominating the Market

  • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Eisai Co., Ltd.
  • Allergan, Inc.
  • TauRx Therapeutics Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Siemens Healthcare GmbH
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • Bayers AG


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved